Korean J Fam Pract.  2022 Dec;12(5):340-345. 10.21215/kjfp.2022.12.5.340.

Effectiveness of Regdanvimab and Remdesivir in Patients with COVID-19 at a Single Hospital

• Kim S
• Jeong HS
• Lim J
• Lee JY
• Ko J
• Suh SJ
• Yoon YJ

• KMID: 2536829
• DOI: http://doi.org/10.21215/kjfp.2022.12.5.340

Abstract

Background
This study examined the clinical effectiveness of regdanvimab and remdesivir in patients hospitalized with COVID-19.
Methods
This retrospective cross-sectional study analyzed the medical records of 128 patients hospitalized with COVID-19 at a hospital in Seoul from 17th December 2020 to 16th February 2022. Demographic data, the hospitalization period, presence of pneumonia on chest X-ray, oxygen treatment period while hospitalized, and discharge place were collected for all patients.
Results
Of the total number of patients, 112 (87.5%) received only regdanvimab, 13 (10.2%) received regdanvimab plus remdesivir, and 3 (2.3%) received neither treatment (the non-medicine group). The hospital stay was significantly shorter in those who received regdanivimab alone or regdanivimab plus remdesivir (9.1±3.1 and 11.6±3.4 days, respectively) compared with the non-medicine group (27.0±14.7 days; P=0.002). The duration of oxygen treatment via nasal prongs in the three groups, i.e., the non-medicine group, those who received regdanivimab alone, and those who received regdanivimab plus remdesivir, was 22.0±19.2, 0.5±2.0, and 3.5±5.7 days, respectively, and was significantly shorter in those who received drug therapy (P=0.031). The rate of discharge to home was also considerably higher in those who received regdanivimab alone or regdanivimab plus remdesivir (97.3% and 100.0%) than in the non-medicine group (33.3%) (P=0.004). Medication use for treating COVID-19 reduced transfer rates to tertiary hospitals and mortality (odds ratio, 0.045; 95% confidence interval, 0.002–0.955; P=0.047).
Conclusion
Use of COVID-19 medicines shortened the hospitalization period and duration of oxygen treatment in inpatients and significantly lowered the rates of transfer to tertiary hospitals and death after treatment.

Keyword

COVID-19; Regdanvimab; Remdesivir; Treatment Outcome